Advertisement
Singapore markets open in 12 minutes
  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     
  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     
  • Dow

    39,118.86
    -45.24 (-0.12%)
     
  • Nasdaq

    17,732.60
    -126.10 (-0.71%)
     
  • Bitcoin USD

    62,745.06
    +1,787.42 (+2.93%)
     
  • CMC Crypto 200

    1,297.76
    +13.93 (+1.09%)
     
  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     
  • Gold

    2,335.00
    -4.60 (-0.20%)
     
  • Crude Oil

    81.71
    +0.17 (+0.21%)
     
  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     
  • Nikkei

    39,863.22
    +280.14 (+0.71%)
     
  • Hang Seng

    17,718.61
    +2.11 (+0.01%)
     
  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     
  • Jakarta Composite Index

    7,063.58
    -6,967.95 (-49.66%)
     
  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes on Friday:

Nike Inc., down $18.82 to $75.37.

The global sportswear giant expects its revenue will slip during the current fiscal year.

Infinera Corp., up 83 cents to $6.09.

Nokia is buying the communications equipment maker for about $2.3 billion.

Kura Sushi USA Inc., down $19.30 to $63.09.

The sushi chain gave investors a disappointing fiscal third-quarter financial update.

Accolade Inc., down $2.81 to $3.58.

The healthcare technology company cut its revenue forecast for the fiscal year.

Protagonist Therapeutics Inc., up $2.77 to $34.65.

ADVERTISEMENT

The biopharmaceutical company will join the S&P Small-Cap 600 on July 3.

PTC Therapeutics Inc., down $4.08 to $30.58.

European regulators rejected the biopharmaceutical company's Duchenne muscular dystrophy treatment.

Freeport-McMoRan Inc., up 28 cents to $48.60.

The copper miner gained ground along with prices for the base metal.

Crown Crafts Inc., up 23 cents to $5.23.

The maker of infant and toddler bedding reported fiscal fourth-quarter earnings and revenue gains.